236 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case report highlights the potential for Tirzepatide to address alcohol use disorder in patients with significant metabolic comorbidities. Given the high prevalence of type 2 diabetes and obesity in individuals w…
This review underscores the rapid and profound evolution of obesity pharmacotherapy, offering unprecedented hope for patients struggling with chronic weight management. The development of highly effective drugs like G…
The development of oral GLP-1 RAs represents a significant leap forward, offering a more convenient and patient-friendly option that can greatly improve adherence to treatment for Type 2 Diabetes. Furthermore, the adv…
This review underscores the transformative potential of GIP receptor-based therapies as a powerful new class of drugs for obesity management. The impressive weight loss and metabolic improvements observed suggest thes…
This research highlights the potent renoprotective capabilities of multi-agonist incretin therapies, particularly Retatrutide, in managing Diabetic Kidney Disease. The superior efficacy of Retatrutide, which targets G…
This comprehensive comparison provides crucial evidence for clinicians and patients, guiding treatment decisions for obesity and overweight. The identification of most effective agents can lead to more personalized an…
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This review underscores a transformative era in obesity management, moving beyond modest weight loss to therapies offering substantial and sustained reductions. The comprehensive overview provided by the authors is cr…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This review underscores the transformative potential of GLP-1RAs in addressing the global obesity epidemic and its related health burdens. The significant and sustained weight loss observed with these agents, coupled …
This comprehensive meta-analysis provides strong evidence supporting retatrutide's exceptional efficacy and acceptable safety profile, positioning it as a highly promising therapeutic option for individuals with obesi…
This research is profoundly significant as it uncovers a direct cardiac effect of retatrutide, distinct from its well-documented metabolic actions. Understanding these direct myocardial influences is paramount for dev…
Antiobesity medications offer a dual therapeutic strategy for managing both obesity and the often-coexisting MASLD, a condition with limited approved treatments. This review highlights their potential to become a corn…
This review underscores the transformative potential of incretin-based therapies in combating the complex challenges of obesity and its comorbidities. By providing a comprehensive overview of their efficacy and safety…
This study provides crucial insights into the direct cardiac actions of retatrutide, suggesting it may have a beneficial or at least neutral impact on heart muscle function. Understanding these direct effects is vital…
This study provides compelling evidence that Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, offers direct and indirect benefits for kidney health in individuals with Type 2 Diabetes …
This comprehensive NMA provides crucial evidence supporting the superior efficacy of multi-receptor agonists like retatrutide and tirzepatide over single GLP-1 RAs for significant weight loss in adults with overweight…
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating…
This research provides crucial insights into the mechanism of action of retatrutide beyond its known effects on glucose and weight regulation, highlighting its potential role in lipid metabolism. Understanding that re…
This review underscores the rapid evolution of pharmacotherapy for obesity, moving beyond traditional approaches to highly effective hormonal analogues that mimic natural satiety signals. The findings suggest a future…
This review highlights the significant potential of triple agonists to offer a more potent and comprehensive therapeutic strategy for obesity and its associated metabolic complications. The synergistic activation of G…
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This review underscores the transformative potential of novel GLP-1-based medications to significantly advance the treatment of Type 2 Diabetes and Obesity. The enhanced efficacy in weight loss and glycemic control, c…
This review provides a crucial, up-to-date resource for healthcare providers, offering a clear understanding of the current landscape of obesity pharmacotherapy. It underscores the paradigm shift towards highly effect…
Repurposing glucagon represents a significant paradigm shift in the treatment of obesity and type 2 diabetes, offering a novel and powerful approach beyond current single-target therapies. By harnessing its beneficial…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
This systematic review provides compelling evidence that next-generation incretin agonists offer superior efficacy for both weight management and glycemic control in overweight and obese individuals. The substantial w…
The development of Retatrutide represents a significant advancement in the pharmacological treatment of obesity and type 2 diabetes, offering a highly potent and comprehensive therapeutic option. Its unique triple-ago…
The insights gained from this study are crucial for advancing personalized treatment strategies for individuals with co-occurring obesity and Binge Eating Disorder. By understanding how GLP-1 analogues interact with b…
The systematic review consistently demonstrated that tirzepatide led to significant and dose-dependent reductions in body weight across various populations, including individuals with obesity and those with type 2 dia…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…